Glucuronide prodrugs of tofacitinib

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10472366
APP PUB NO 20180258094A1
SERIAL NO

15914189

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THERAVANCE BIOPHARMA R&D IP, LLC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Long, Daniel D San Francisco, US 116 924
Loo, Mandy M San Jose, US 3 5
Wilton, Donna AA San Francisco, US 12 28

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 12, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 12, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00